Amylin Cuts 60 Jobs

Xconomy San Diego — 

San Diego-based Amylin Pharmaceuticals (NASDAQ: AMLN) has cut 60 jobs, or about 4 percent of its workforce, according to a recent story in the Union-Tribune. The cuts happened within a few specific areas of the company, including R&D, spokeswoman Anne Erickson said. “The R&D changes do not signal a move away from research at Amylin,” Erickson said in an e-mail. “Rather, we are changing how we source innovation and will look to both internal and external sources to find ways to continue to fulfill our mission of bringing innovative medicines to patients.”